Kamada Ltd. (NASDAQ:KMDA) Short Interest Up 2,002.5% in February

Kamada Ltd. (NASDAQ:KMDA) saw a large growth in short interest during the month of February. As of February 15th, there was short interest totalling 166,100 shares, a growth of 2,002.5% from the January 31st total of 7,900 shares. Currently, 0.5% of the shares of the stock are short sold. Based on an average daily trading volume, of 175,600 shares, the days-to-cover ratio is presently 0.9 days.

Kamada Stock Performance

Shares of KMDA stock opened at $6.89 on Friday. Kamada has a fifty-two week low of $4.74 and a fifty-two week high of $9.15. The stock has a 50 day moving average price of $7.01 and a two-hundred day moving average price of $6.10. The company has a market capitalization of $396.04 million, a P/E ratio of 24.61, a PEG ratio of 0.97 and a beta of 0.99.

Wall Street Analyst Weigh In

Separately, HC Wainwright reiterated a “buy” rating and issued a $11.00 price objective on shares of Kamada in a research report on Friday, January 10th.

Institutional Trading of Kamada

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Aristides Capital LLC increased its stake in shares of Kamada by 12.1% during the fourth quarter. Aristides Capital LLC now owns 63,485 shares of the biotechnology company’s stock valued at $387,000 after buying an additional 6,850 shares during the period. Geode Capital Management LLC increased its stake in shares of Kamada by 5.6% during the fourth quarter. Geode Capital Management LLC now owns 29,289 shares of the biotechnology company’s stock valued at $178,000 after buying an additional 1,549 shares during the period. NewEdge Advisors LLC increased its stake in shares of Kamada by 54.2% during the fourth quarter. NewEdge Advisors LLC now owns 23,496 shares of the biotechnology company’s stock valued at $143,000 after buying an additional 8,260 shares during the period. Plato Investment Management Ltd purchased a new position in shares of Kamada during the third quarter valued at approximately $117,000. Finally, Public Employees Retirement System of Ohio purchased a new position in shares of Kamada during the third quarter valued at approximately $77,000. Institutional investors own 20.38% of the company’s stock.

About Kamada

Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its commercial products include KAMRAB/KEDRAB for treating prophylaxis of rabies; CYTOGAM for Prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; KAMRHO (D) IV for immune thermobocytopunic purpura; and Echis coloratus and Vipera palaestinae Antiserum for the treatment of snake bite.